Program Description
The recent approvals of additional HER2-targeted agents for treatment of metastatic breast cancer have contributed to improved outcomes for patients with HER2-positive disease, but have also complicated treatment selection. To provide appropriate access and cost-effective use of HER2-targeted treatments, managed care professionals need to be familiar with the clinical data and indications for the use of these agents. In this panel discussion, managed care experts will differentiate among available and emerging agents, as well as detail how these agents fit within guideline recommendations to support optimal treatment sequencing. Panelists will discuss and debate considerations for choosing among guideline-recommended therapies and the impact of later lines of therapy on patient outcomes. Managed care professionals will incorporate strategies to overcome barriers and optimize treatment approaches to ensure cost-effective, outcomes-based, concordant treatment for patients with HER2-positive metastatic breast cancer.
Target audience: Oncology and managed care pharmacists
Type of activity: Application
Release date: August 30, 2024
Expiration date: August 30, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the current treatment landscape and guideline recommendations for the use of HER2-targeted therapies in the treatment of HER2-positive metastatic breast cancer (MBC)
- Analyze the recent clinical trial data assessing novel therapies and combinations targeting HER2-positive MBC and their potential clinical impact
- Explore the operational and managed care impact of new and emerging data in HER2-positive MBC treatment, including formulary, pathways, resources, cost, and patient outcomes
Rose DiMarco, PharmD, BCPS, BCOP
Oncology Pharmacy Manager
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Laura J. Hackett, PharmD, BCOP
Clinical Pharmacy Manager, Hematology/Oncology
Department of Pharmacy Services
Dartmouth Cancer Center, Dartmouth Health
Lebanon, New Hampshire
Laura R. Bobolts, PharmD, BCOP
Senior Vice President, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-242-H01-P. The activity is available for CE credit through August 30, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Rose DiMarco, PharmD, BCPS, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Gilead Sciences, Inc, Lilly
Speakers Bureau: Lilly
Laura J. Hackett, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.
Moderator
Laura R. Bobolts, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Medical reviewer Lilia Davenport, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Novartis AG, Daiichi Sankyo, Inc
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms